All In Biotech

Drug Trial Radar · NCT03659058

Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR

Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After Achieving Sustained Virological Response

Last checked: Nov 20, 2026Latest source record: Nov 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Mar 2, 2016

Primary completion

Aug 2018

Study completion Aug 1, 2018

Sponsor

Lead sponsor
Zagazig UniversityGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Sep 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

with the introduction of Direct-acting antiviral agents in the management of HCV, the scope of inclusion criteria had been widened to include patients with compensated cirrhosis and even in special situations patients with decompensated liver disease; a chance that was not offered by the limited and strict inclusion criteria needed for treatment by pegylated interferon-based regimen. this made the number of patients with progressive liver fibrosis of cirrhosis had been inv=creased even after achieving SVR. the debate about the impact of SVR on halting fibrosis progression had risen; some studies postulated that patients benefit from an SVR through reduction of mortality, morbidity, and improved quality of life ; however, some patients may maintain their level of fibrosis or even progress to cirrhosis despite achieving SVR and the risk for HCC remains even after virologic eradication.

Conditions

  • Fibrosis, Liver

Interventions

  • silymarinDrug

    silymarin 140 three times daily

  • Ursodeoxycholic AcidDrug

    Ursodeoxycholic Acid 500

  • AntioxidantsDrug

    Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg

  • ColchicineDrug

    Colchicine 0.6

  • FOLLOW UPOther

    follow up by abdominal ultrasound and fibroscan every 6 month for 1 year

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in liver stiffness measurement by FibroscanTime frame: 1 year
  2. Improved portal hypertension parametersTime frame: 1 year
  3. Improved splenic stiffness measurementTime frame: 1 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.